ReviewAnnals of translational medicine2025
Management of hypertension in specific populations: a review.
Review in Annals of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension is a widespread global health issue that disproportionately affects certain populations, including self-identified Blacks, the older persons, patients with chronic kidney disease (CKD), and kidney transplant recipients. Hypertension disproportionately affects self-identified Black individuals, with a prevalence of 57.1% compared to 43.6% in non-Hispanic White individuals. This disparity is linked to social determinants of health. Furthermore, APOL1 genetic variants found in self-identified Black individuals increase their susceptibility to kidney injury and CKD, which can subsequently contribute to hypertension. Although in the past thiazide diuretics and calcium channel blockers (CCBs) were suggested to be more effective in Black adults, combination therapy is now generally required, with comparable efficacy across populations. In the older persons, hypertension affects approximately 70% of individuals over the age of 65 years, often manifesting as isolated systolic hypertension (ISH). Trials like the SPRINT study (Systolic Blood Pressure Intervention Trial) have demonstrated the benefits of lowering systolic blood pressure (SBP) to less than 120 mmHg; however, treatment must take into account factors like orthostatic hypotension and frailty. Patients with CKD have a hypertension prevalence of 80-85%. The KDIGO (Kidney Disease: Improving Global Outcomes) 2021 guidelines recommend maintaining an SBP of less than 120 mmHg based on the SPRINT trial, although this goal may increase the risk of acute kidney injury (AKI). Renin-angiotensin-aldosterone system (RAAS) blockers are typically preferred for those with proteinuric CKD. Kidney transplant recipients also experience high rates of hypertension, with approximately 85% affected. The KDIGO 2021 guidelines suggest a blood pressure (BP) target of less than 130/80 mmHg in kidney transplant patients, with a focus on promoting graft survival. Dihydropyridine CCBs and angiotensin receptor blockers are commonly preferred treatments in kidney transplant patients, especially for patients with proteinuric kidney disease. This review synthesizes current evidence regarding the unique challenges and management strategies for hypertension in these specific groups. It examines the prevalence, underlying mechanisms, and treatment considerations while emphasizing the importance of individualized care to achieve optimal BP control and reduce cardiovascular risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.